Oncology Corporate Profile
Atterocor is a drug development company focused on a novel treatment for adrenal cancer. The company is accelerating the development of a new adrenal-targeting therapy for the treatment of adrenocortical carcinoma (ACC) patients. ACC is a rare disease with a poor prognosis, extremely limited treatment options and significant unmet medical need.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|ATR-101||ACAT 1 inhibitor||Adrenocortical carcinoma (ACC)||I|